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Summary Angiogenesis is thought to be an important factor for tumour growth and metastatic spread, and microvessel counts may provide
useful prognostic information for several tumour types. To investigate the prognostic impact of angiogenesis in endometrial carcinoma
patients, the intratumour microvessel density, which was determined immunohistochemically, has been related to survival. Sixty patients with
endometrial carcinoma with long (median 19 years) and complete follow-up have been studied. Patients with increased mean microvessel
density (MVDmean > 68 mm-2) had a significantly shorter 5-year survival compared with the rest (57% vs 90%, P = 0.004). In multivariate
survival analyses, MVDmean had an independent prognostic impact (P = 0.03) when FIGO stage, histological type, histological grade as well
as nuclear p53 protein expression was adjusted for. These findings indicate that intratumour microvessel density may contribute additional
prognostic information to that obtained from the known risk factors and may be helpful in identifying endometrial carcinoma patients at high
risk for disease progression.
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Angiogenesis is of crucial importance for tumour growth and
development of metastases (Folkman, 1989; Hanahan and
Folkman, 1996). Tumour cells capable of rapid proliferation are
thought to be dependent on persistent blood vessels to expand, and
the absence ofneovascularization will consequently restrict tumour
growth (Folkman, 1989). Vascularization is likewise considered to
permit shedding of cells from a primary tumour to distant body
sites, thus facilitating the metastatic process (Weidner, 1995). From
experimental models, it seems evident that the angiogenic switch
occurs early in the process of tumorigenesis (Hanahan and
Folkman, 1996), with the induction of angiogenesis as a discrete
component of the tumour phenotype activated during the early
stages. The intensity oftumour vascularization is thought to reflect
the angiogenic activity generated by the neoplastic cells or the
supporting stroma (Weidner et al, 1992; Holmgren et al, 1995).
Studies of breast, lung and prostate cancer as well as other
tumour types have indicated that increased microvessel density
within the tumours is associated with the metastatic potential, and
in some studies increased vascularity has been identified as a
prognostic factor (Weidner et al, 1991, 1992; Gasparini et al, 1994;
Fontanini et al, 1995; Weidner, 1995). In the endometrium, malig-
nancy and increased tumour stage was associated with increased
microvessel density (Abulafia et al, 1995). A comparison of
primary tumour vascularity among patients with and without
recurrent disease indicated a potential prognostic importance,
although the number of patients was low (Kirschner et al, 1996).
To our knowledge, the present study is the first relating micro-
vessel density to survival for endometrial carcinoma patients
in comparison with other clinicopathological variables and
p53 protein expression, which has recently been implicated as a
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regulatory factor for vascular proliferation (Dameron et al, 1994).
Our results indicate that microvessel density may provide impor-
tant prognostic information for this group ofpatients.
MATERIALS AND METHODS
A prospective study of prognostic factors for endometrial carci-
noma patients was started in January 1981 at the Department of
Gynaecology and Obstetrics at Haukeland University Hospital in
Norway. This is a referral hospital forpatients in Hordaland county
with approximately 400 000 inhabitants (about 10% of the total
Norwegian population). In 1981-85, data regarding patient charac-
teristics and treatment was collected for 60 patients primarily
treated by surgery for endometrial carcinoma at Haukeland
University Hospital. The treatment protocol for the period was
abdominal hysterectomy and bilateral salpingoophorectomy as
initial treatment. After primary operation, 54 (90%) ofthe patients
had no residual tumour. No patient received preoperative radiation
therapy. Adjuvant radiation therapy was given to patients with
myometrial tumour infiltration without distant metastases, intrav-
aginal radiation to patients with highly and moderately dif-
ferentiated tumours infiltrating less than half of the myometrium
and pelvic external radiation (50 Gy) to the rest of the patients.
Advanced age or intercurrent disease, however, resulted in a less
aggressive treatment among 14 patients. The median age at time of
primary operation was 66 years (range 37-86 years). All patients
were retrospectively staged according to the FIGO 1988 criteria
(Mikuta, 1993). The tumour specimens were reclassified and
graded by one pathologist (LAA) according to WHO 1994
(Scully et al, 1994).
Patient selection
Patient age, FIGO stage, treatment and survival were compared for
the patients from Haukeland University Hospital included in this
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study with the rest of the patients from Hordaland county treated
for endometrial carcinoma in the period. Curative surgical treat-
ment was more often possible in the study group than in the rest of
the population, which is in accordance with the current practice in
the region, i.e. that women not available for curative treatment
either because ofadvanced age or serious intercurrent or extensive
disease are less often referred to the University Hospital for
primary surgery. Except for this, there were no significant differ-
ences in the other patient characteristics. Among the patients
treated for cure, no significant difference in survival was found for
the study group from Haukeland University Hospital compared
with the rest ofthe patients in the county ofHordaland.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed,
paraffin-embedded specimens. Haematoxylin and eosin-stained
sections were used to select a representative, invasive area of the
tumour, and 5-jm-thick sections were stained immunohisto-
chemically.
After protease-induced epitope retrieval, the vessels were high-
lighted by staining endothelial cells for factor VIII-related antigen
(code no. A-082, Dako, Copenhagen) according to the standard-
ized avidin-biotin method provided by the manufacturer.
For p53 staining, the sections were subjected to microwave
epitope retrieval (750 W, 2 x 5 min in citrate buffer, pH 6) before
staining with the monoclonal antibody DO-7 (code no. M-7001,
Dako) according to the avidin-biotin method.
The extent ofnuclearp53 staining was recorded by a semiquan-
titative and subjective grading, considering both the intensity of
staining and the proportion of cells showing an unequivocal posi-
tive reaction as described previously (Aas et al, 1996). Intensity
was recorded as 0 (no staining) to 3 (strong staining), percentage
ofnuclear staining as 0 (no tumour cells positive), 1 (<10% ofthe
tumour cells), 2 (positive staining in 10-50% of the tumour cells)
and 3 (positive staining in >50% of the tumour cells). A staining
index was calculated as the product of the staining intensity and
the staining area.
The slides were counterstained with Harris haematoxylin.
Blinded for patient characteristics and outcome, the slides were
evaluated individually by two of the authors (HS, LAA) in a
standard light microscope for immunohistochemical staining.
Vessel counts
The invasive tumours were often heterogeneous with respect to the
amount and distribution of microvessels, and the sections were
scanned at low magnifications (x40 and xlOO) to identify the most
vascular area of the tumour ('hot spot'). Within these areas, a
minimum often fields atx250 magnification (0.4243 mm2 per field)
were examined. Brown-stained endothelial cells or endothelial cell
clusters that were clearly separate from adjacent vessels, tumour
cells or connective tissue elements were considered to be single
countable microvessels, as previously described by Weidner et al
(1991, 1995). The maximum count within any single field
(MVDmaX), the average ofthe three most vascular fields (MVDmean3)
and the average of all fields examined within the 'hot spot' areas
(MVDmeaw) were then recorded and expressed as counts mm-2 as
previously described (Paulsen et al, 1997).MVDmean was considered
to represent the average tumour vascularity ofthe 'hot spot' areas.
Each slide was examined three times blinded for previous
results (HS). The tumours were classified as microvessel rich or
poor (defined by the upper quartile for the last examinations for
each of the three MVD variables). The intraobserver exact agree-
ment between the last two examinations for classifying the
tumours as microvessel rich vs poor was found to be 87% for
MVDmean (Kappa = 0.64), 81% for MVDmaX (Kappa = 0.45) and
79% forMVDmean3 (Kappa = 0.49).
Follow-up
At the closing date of the study, 30 June 1996, the follow-up
period for the survivors was average 11 years (range 8-15 years)
or until death, with no patient lost due to insufficient follow-up
data. Information about survival was achieved from the medical
records and correspondence with the primary physician. The data
were cross-checked with the Cancer Registry ofNorway, which is
matched against the Register ofStatistics ofDeaths Norway.
Statistics
Comparison of groups was performed using the chi-square or
Mann-Whitney tests. Reproducibility was assessed using Kappa
statistics. Univariate survival analyses of time to death due to
endometrial carcinoma (cause-specific death) was performed
using the product-limit procedure (Kaplan-Meier method), with
the time of primary operation as the entry date. The Mantel-Cox
test was used to compare the survival curves for groups ofpatients
defined by categories ofeach variable. The variables with signifi-
cant impact on survival in univariate analyses (P < 0.05) were
further examined by log-minus-log plot to decide how these vari-
ables should be incorporated in the multivariate Cox proportional
hazards regression model (Cox, 1972). All patients in FIGO stage
I (IA, IB and IC) and II were analysed in one group in the multi-
variate model, as a result of there being no deaths in FIGO stage
IA/IB and only one patient in FIGO stage II. As MVDmaX9
MVDmean3 and MVDmean all express microvessel density and are
strongly correlated, they were introduced separately into the multi-
variate model with the traditional clinicopathological variables for
estimation of hazard ratios as a measure of effect. Data were
analysed using the Biomedical Computer Programs (BMDP)
(Dixon, 1992).
RESULTS
Table shows the relationship between microvessel counts and
standard clinicopathological variables as well as p53 immuno-
staining. A significant association between increased microvessel
density (MVDmax' MVDmean3 and MVDmean) and FIGO stage III
and IV was demonstrated. No relationship between microvessel
counts and p53 expression was found (Table 1). There was a
tendency for stronger p53 protein expression with increasing
FIGO stage, although this was not statistically significant
(P = 0.09, chi-square test).
Based on microvessel counts for MVDmax, MVDmean3 and
MVDmean, the patients were divided into four categories defined by
the lower quartile, median and upper quartile. The survival was
significantly decreased in the category with highest values for
MVDmean (P = 0.004), MVDmean3 (P = 0.01) andMVDmax (P =0.01),
whereas there was no difference between the other three categories
(Figure 1). In later analyses, the patients were therefore divided in
two groups by the upper quartile (Table 2).
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Table 1 Microvessel density (vessel counts mm-2) related to standard clinicopathological variables and p53 protein expression in 60 patients with endometrial
carcinoma
Variable n MVDm a PLvalueb MVD. a' P.valueb MVD,.' P.valueb
Patient age (years) 0.58 0.43 0.54
<66 31 73 66 49
>66 29 75 71 52
FIGO stage 0.01 0.004 0.003
I/ll 50 71 64 47
III/IV 10 101 92 71
Histological type 0.24 0.19 0.17
Endometroid/adenoacanthoma/adenosquamous 54 73 66 49
Serous papillary/clear cell 6 120 108 75
Histological grade 0.21 0.18 0.17
Highly/moderately 50 73 66 49
Poorly 10 92 85 59
p53 stainingc 0.87 0.75 0.56
Weak 47 73 66 49
Strong 13 68 68 52
aMVD,,,I microvessel count in the most vascular field (x250); MVDmean3, average microvessel count in the three most vascular fields examined; MVDmean'
average microvessel count in all fields examined; median values for microvessels counts are given for each group. bMann-Whitney test. cWeak, staining
index< 4; strong, staining index >4. n, number of cases.
MVDma MVDmean3 and MVDmean were all found to be signifi-
cantly associated with survival. This was also the case for FIGO
stage, histological type, histological grade and nuclear p53 protein
expression (Table 2).
In multivariate analyses of survival, MVDmean was an indepen-
dent prognostic factor (P = 0.03) when adjusted for FIGO stage,
histological type, histological grade and nuclear p53 protein
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Figure 1 Univariate survival analysis according to mean microvessel
density (MVDmean) (Kaplan-Meier method), with death of endometrial
carcinoma as end point. MVDmean < 68 vs MVDmean > 68, P= 0.004
(Mantel-Cox test). *, MVDmean < 41 (n = 17); El, MVDmean 41-52 (n = 17);
A, MVDmean 53-68 (n = 12); x, MVDmean > 68 (n = 14)
expression. MVDmaX' MVDmean3 and MVDmean were all analysed
separately in the multivariate models, and MVDmean was found to
be the strongest prognostic factor. Independent prognostic impact
was also found for FIGO stage (P = 0.0001), whereas nuclear p53
protein expression showed a borderline influence (P = 0.08).
Histological grade (P = 0.20) and histological type (P = 0.29) lost
their prognostic influence in the final multivariate analysis.
However, when only tumour variables were included in the Cox
analysis, MVDmean' p53 protein expression and histological type
remained as significant and independent predictors of survival
(Table 3).
DISCUSSION
Our finding that increased microvessel count is significantly asso-
ciated with decreased survival is in accordance with studies on
other cancer forms, particularly breast cancers (Weidner et al,
1991, 1992; Gasparini et al, 1994; Fontanini et al, 1995; Weidner,
1995). The absolute microvessel counts mm-2 for endometrial
carcinomas are somewhat lower than those reported for breast
tumours, using the same method (Weidner et al, 1991). This could
reflect a biological difference between endometrial and breast
carcinomas. However, the microvessel counts in our study seem to
be higher than those reported by Kirschner et al (1996) in a small
study of endometrial carcinomas, although different techniques
were used.
The significant association between microvessel density and
metastatic disease demonstrated in our study has been reported for
other cancer types (Weidner et al, 1991, 1992, 1993; Gasparini et
al, 1994; Fontanini et al, 1995; Weidner, 1995). These results are
in accordance with angiogenesis being a crucial factor in the
metastatic process and thus for the progression of a malignant
disease (Folkman, 1989).
The regulatory role of p53 on angiogenesis has been discussed
recently (Dameron et al, 1994). In an experimental model using
fibroblasts, it has been shown that altered p53 may reduce the
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Table 2 Univariate survival analysis for 60 patients with endometrial carcinoma (Kaplan-Meier method)
Variable No. of patients No. of deaths 5-Year survival % (s.e.) P.valuea
Patient age (years) 0.51
<66 31 5 87 (6.3)
>66 29 6 78 (8.1)
FIGO stage <0.0001
I/ll 50 4 94 (3.6)
liI 8 5 30 (17.5)
IV 2 2 0
Histological type <0.0001
Endometroid/adenoacanthoma/adenosquamous 54 7 88 (4.6)
Serous papillary/clear cell 6 4 33 (19.3)
Histological grade 0.03
Highly/moderately 50 7 87 (5.0)
Poorly 10 4 60 (15.5)
p53 stainingb 0.01
Weak 47 6 89 (4.7)
Strong 13 5 57 (14.6)
Microvessel density (MVD)c
MVDm. 0.01
<97mm-2 45 5 90(4.6)
>97 mm-2 15 6 60 (12.7)
MVD .an3 0.01
<85 mm-2 45 5 90 (4.6)
>85mm-2 15 6 60(12.7)
MVDmean 0.004
<68mm-2 46 5 90(4.6)
>68mm-2 14 6 57 (13.2)
aMantel-Cox test for difference in survival between groups. bWeak, staining index <4; strong, staining index > 4. CMVDmax, microvessel count in the most
vascular field (x250); MVDmean3, average microvessel count in the three most vascular fields examined; MVDmean' average microvessel count in all fields
examined, divided in two groups by the upper quartile.
Table 3 Multivariate analysis of the tumour features in endometrial
carcinoma patients based on the Cox proportional hazards regression model
Regression
Variable coefficient f 95% Cl P-values
Histological typeb 2.37 0.37-4.37 0.023
Histological gradec 0.90 -1.26-3.06 0.39
p53 stainingd 1.71 0.26-3.16 0.024
MVDmear 1.64 0.35-2.93 0.014
aLR test. bEndometroid/adenoacanthoma/adenosquamous vs serous
papillary/clear cell. cHighly/moderately vs poorly differentiated. dindex <4 vs
index > 4. eAverage microvessel count in all fields examined,
MVDm.an <68 mm-2 vs MVDmean >68 mm-2.
expression of thrombospondin-1, which is a potent inhibitor of
vessel formation (Dameron et al, 1994). Further, p53 mutations
have been related to induction ofvascularendothelial growthfactor
(VEGF) expression (Kieser et al, 1994). In our present study, no
significant association between nuclearp53 protein expression and
microvessel density was present, which is in accordance with
reports on breast cancer(Gasparini et al, 1994; Costello et al, 1995;
Paulsen et al, 1997), arguing against a simple relationship between
p53 protein expression and microvessel density.
Adjuvant treatment for endometrial carcinoma is based on infor-
mation about prognostic factors, such as disease stage, histological
type andhistological grade (Abler and Kj0rstad, 1991; Rose, 1996).
These factors have beenextensively studied(Mikuta, 1993), and our
present findings generally support the view that FIGO stage, as
revised in 1988, is a highly significant prognosticator. Recently,
molecular markers have been introduced as potential prognostic
factors that could improve our ability to identify high-risk patients
with endometrial carcinoma (Pisani et al, 1995). P53 protein expres-
sion has been shown to be an independentprognostic factor in some
studies (Ito et al, 1994; Pisani et al, 1995; Geisler et al, 1996; Soong
et al, 1996), while others have been unable to confirm this (Inoue et
al, 1994; Lukes et al, 1994; Reinartz et al, 1994). We found a signif-
icant prognostic influence of nuclear p53 protein expression when
only tumour variables were investigated, whereas p53 staining
showed a borderline significance in the multivariate analysis with
FIGO stage included. The relatively small number ofpatients in this
study should, however, be kept in mind.
In conclusion, our findings suggest that microvessel density
may be a helpful tool to identify endometrial carcinoma patients at
higher risk ofdeath. The increasing optimism regarding the use of
angiogenesis inhibitors (Baillie et al, 1995; Hanahan and Folkman,
1996) may further motivate the quantitation of intratumour
microvessel density for decisions regarding therapeutic strategies.
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